Patent claims:

- 1. A process for identifying inhibitors of a eukaryotic potassium channel, in which
 - a) a mutated S. cerevisiae cell is used which does not express the three endogenous potassium channels TRK1, TRK2 and TOK1;
 - b) a eukaryotic potassium channel is expressed heterologously in this mutated S. cerevisiae cell;
 - c) the mutated S. cerevisiae cell is incubated together with a substance to be tested:
- 10 and
 d) the effect of the substance to be tested on the eukaryotic potassium

channel is determined.

- The process as claimed in claim 1, wherein the genes TRK1, TRK2 and TOK1
 are switched off in the mutated S. cerevisiae cell (Δtrk1, Δtrk2, Δtok1).
 - 3. The process as claimed in one or more of claims 1 and 2, wherein the eukaryotic potassium channel is a human potassium channel.
- 20 4. The process as claimed in one or more of claims 1 to 3, wherein the eukaryotic potassium channel is a HERG1, Kv1.5 or gplRK1.
- 5. The process as claimed in one or more of claims 1 to 4, wherein the eukaryotic potassium channel is mutated.
 - 6. The process as claimed in one or more of claims 1 to 5, wherein the eukaryotic potassium channel is present in a yeast expression plasmid.
 - 7. The process as claimed in one or more of claims 1 to 6, wherein the mutated S. cerevisiae cell expresses constitutively a growth reporter.

SUB C3

5

H. H. H. T. Man V. J. D. Yang Kama. Jr. Hing. R. J. T. Hing. R. J. T. T. Hang. R. J. T. T. Hang. R. J. J. Hang. Res. J. Hang. Re

<u>"</u>1

SA BI

25

8.

The process as claimed in one or more of claims 1 to 7, wherein a substance to be tested, which has an effect on the eukaryotic potassium channel, inhibits the growth of the mutated S cerevisiae cell.

The process as claimed in one or more of claims 1 to 7, wherein the effect of a substance to be tested on the eukaryotic potassium channel is determined by measuring the cell count of the mutated S. cerevisiae cells.

- 10. The process as claimed in claim 9, wherein the cell count is determined via the fluorescence or luminescence of a constitutively expressed growth reporter.
 - 11. A mutated S. cerevisiae cell in which the endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed.
- 15 12. A mutated S. cerevisiae cell in which the genes TRK1, TRK2 and TOK1 are switched off.
 - 13. A mutated S. cerevisiae cell deposited as DSM 13197.
- 20 14. The mutated S. cerevisiae cell as claimed in one or more of claims 11 to 13, which S. cerevisiae cell expresses heterologously a eukaryotic potassium channel.
 - 15. The mutated S. cerevisiae cell as claimed in one or more of claims 11 to 14, wherein the eukaryotic potassium channel is a human potassium channel.
 - 16. The mutated S. cerevisiae cell as claimed in one or more of claims 11 to 15, wherein the eukaryotic potassium channel is a HERG1, Kv1.5 or gpIRK1.
- 30 17. The mutated S. cerevisiae cell as claimed in one or more of claims 11 to 16, wherein the eukaryotic potasium channel is mutated.

15

30

and

and

- 18. A process for the generation of a mutated S. cerevisiae cell which does not express the potassium channels TRK, TRK2 and TOK1, wherein the genes TRK1, TRK2 and TOK1 are destroyed by knock-out.
- 5 19. The use of a mutated S. cerevisiae cell as claimed in one or more of claims 11 to 17 for identifying substances which inhibit the activity of the eukaryotic potassium channel.
 - 20. A process of identifying activators of a eukaryotic potassium channel, in which
 - a) a mutated S. cerevisiae cell is used which does not express the three endogenous potassium channels TRK1, TRK2 and TOK1;
 - b) a eukaryotic potassium channel is expressed heterologously in this mutated S. cerevisiae cell;
 - c) the mutated S. cerevisiae cell is incubated together with a substance to be tested;
 - d) the effect of the substance to be tested on the eukaryotic potassium channel is determined.
 - 20 21. A process of identifying activators of a eukaryotic potassium channel, in which
 - a) a mutated S. cerevisiae cell is used which does not express the three endogenous potassium channels TRK1, TRK2 and TOK1;
 - b) a eukaryotic potassium channel is expressed heterologously in this mutated S. cerevisiae cell;
 - 25 c) the mutated S. cerevisiae cell is incubated together with a substance to be tested in the presence of an inhibitor of the eukaryotic potassium channel;

d) the effect of the substance to be tested on the eukaryotic potassium channel is determined.

- 22. A test kit comprising a mutated S. cerevisiae cell as claimed in any of claims 11 to 17.
- 23. A process for the preparation of a medicament, wherein
- SOB BY
- a) an inhibitor of a eukaryotic potassium channel is identified with the aid of a process as claimed in any of claims 1 to 10,
- b) the inhibitor is prepared or isolated by known chemical processes, and
- c) physiologically acceptable additives are added to the inhibitor.
- 10 24. A process for the preparation of a medicament, wherein
 - a) an activator of a eukaryotic potassium channel is identified with the aid of a process as claimed in either of claims 20 and 21,
 - b) the activator is prepared or isolated by known chemical processes, and
 - c) physiologically acceptable additives are added to the activator.